Side-by-side · Research reference
HGH 191AAvsKPV
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED0/75 cited
BAnimal-StrongAUTO-DRAFTED13/39 cited
HGH 191AA
Recombinant hGH · FDA-Approved
0.024–0.034 mg/kg/dayPediatric GHD dose
2–4 hoursPlasma half-life
191 AASequence length
SQ · Daily · Evening preferred
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
01Mechanism of Action
Parameter
HGH 191AA
KPV
Primary target
Growth hormone receptor (GHR) — JAK2/STAT5 pathway
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Pathway
GHR activation → JAK2/STAT5 → liver IGF-1 synthesis + direct metabolic effects
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Downstream effect
Linear growth, lipolysis, protein synthesis, nitrogen retention, carbohydrate metabolism modulation
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Feedback intact?
No — exogenous GH bypasses hypothalamic-pituitary axis, suppresses endogenous pulsatility
No melanocortin receptor binding
Origin
Recombinant DNA technology — 191 AA, identical to pituitary hGH, no methionyl residue
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Antibody development
Rare — <2% develop binding antibodies, typically non-neutralizing
—
02Dosage Protocols
Parameter
HGH 191AA
KPV
Pediatric GHD
0.024–0.034 mg/kg/day SQ
6–7× per week dosing typical. Brand-specific ranges.
—
Adult GHD
0.004–0.016 mg/kg/day SQ
Start low, titrate based on IGF-1 levels.
—
Turner syndrome
0.045–0.050 mg/kg/day SQ
—
Idiopathic short stature
0.037 mg/kg/day SQ
—
AIDS wasting
0.1 mg/kg/day SQ (high-dose)
Short-term indication. Monitor glucose.
—
Frequency
Once daily, typically evening
Evening administration mimics physiological GH pulse.
Daily or 2–3× per week
Evidence basis
FDA-approved / decades of RCT data
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Monitoring
IGF-1, glucose, thyroid function, bone age (children)
—
Duration
Years (children until epiphyseal closure); indefinite (adult GHD)
4–8 weeks per cycle
Lower / starter dose
—
100 mcg / day
Reconstitution
—
Bacteriostatic water (SQ form)
Timing
—
No specific time; often taken with / before meals (oral)
Half-life
—
Hours (estimated; rapid tissue uptake)
03Metabolic / Fat Loss Evidence
Parameter
HGH 191AA
KPV
Primary fat target
Visceral and subcutaneous adipose tissue
—
Mechanism
Lipolysis via hormone-sensitive lipase activation, FFA oxidation
—
Effect on lean mass
Significant lean mass increase (protein synthesis, nitrogen retention)
—
Insulin sensitivity
Acute insulin resistance (anti-insulin effect); chronic neutral-to-improved via fat loss
—
IGF-1 elevation
Dose-dependent, significant — primary anabolic mediator
—
Glucose metabolism
Hyperglycemia risk, especially high doses (AIDS wasting)
—
Body composition
↓ fat mass, ↑ lean mass, ↑ bone mineral density (children)
—
Clinical context
FDA-approved for AIDS wasting (cachexia). Off-label use for body recomposition lacks long-term safety data.
—
04Side Effects & Safety
Parameter
HGH 191AA
KPV
Injection site reaction
Lipohypertrophy, lipoatrophy, erythema (rotate sites)
Mild irritation
Fluid retention / Edema
Peripheral edema, arthralgia, carpal tunnel syndrome (dose-dependent)
—
Glucose intolerance
Hyperglycemia, new-onset diabetes (anti-insulin effect)
—
Intracranial hypertension
Benign intracranial hypertension (pseudotumor cerebri) — headache, visual changes, papilledema
—
Slipped capital femoral epiphysis
SCFE risk in children — limp, hip/knee pain (requires surgery)
—
Scoliosis progression
Rapid growth may unmask/progress scoliosis (monitor spine in children)
—
Hypothyroidism
Central hypothyroidism unmasking or worsening (monitor TSH, free T4)
—
Cancer risk
Contraindicated in active malignancy. Theoretical risk in cancer survivors (controversial).
—
Antibody formation
Rare (<2%), typically non-neutralizing. Loss of efficacy if neutralizing antibodies develop.
—
Pancreatitis
Rare. Higher risk in children with certain syndromes (Prader-Willi).
—
Gynecomastia
Adolescent males (physiological during puberty, may be exacerbated)
—
GI symptoms
—
Rare nausea (oral form)
Long-term safety
—
Limited human data
Pregnancy / OB
—
Avoid — insufficient data
Absolute Contraindications
HGH 191AA
- ·Active malignancy or history of cancer (especially childhood cancer survivors with risk factors)
- ·Acute critical illness (post-cardiac surgery, trauma, acute respiratory failure)
- ·Diabetic retinopathy (active proliferative or severe non-proliferative)
- ·Prader-Willi syndrome with severe obesity, sleep apnea, or respiratory impairment
- ·Closed epiphyses (for growth indications)
KPV
- ·Pregnancy / breastfeeding
Relative Contraindications
HGH 191AA
- ·Diabetes mellitus (monitor closely, may require insulin adjustment)
- ·Intracranial lesions or history of intracranial hypertension
- ·Scoliosis (monitor curve progression)
- ·Untreated hypothyroidism (treat before GH initiation)
- ·Severe obesity (assess OSA risk, cardiovascular status)
KPV
- ·Active autoimmune disease (theoretical)
05Administration Protocol
Parameter
HGH 191AA
KPV
1. Reconstitution (if lyophilized)
Add diluent (sterile water or bacteriostatic water per manufacturer) to vial. Swirl gently — do not shake. Solution should be clear, colorless. Concentration varies by brand (e.g., 5 mg or 10 mg per vial).
Add 1 mL bacteriostatic water to vial per labelling.
2. Injection site
Subcutaneous — rotate sites: abdomen, thigh, buttocks, upper arm. Avoid same site within 1 cm for 2 weeks to prevent lipodystrophy.
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
3. Timing
Once daily, evening preferred (6–8 PM or pre-sleep). Mimics physiological nocturnal GH secretion. Consistency is critical.
Morning preferred; oral form taken with / before meals.
4. Storage
Unreconstituted: refrigerate 2–8 °C, protect from light. Reconstituted: refrigerate, use within 14–28 days (brand-specific). Do not freeze.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
27–31G, 4–8 mm insulin syringe or pen device. Pinch skin, 45–90° angle depending on subcutaneous thickness.
29–31G insulin syringe (SQ form).
6. Monitoring
Baseline and periodic: IGF-1 (target age/sex-adjusted midrange), fasting glucose, HbA1c, thyroid function (TSH, free T4), bone age (children), lipid panel. Fundoscopy if headache/visual symptoms.
—
06Stack Synergy
HGH 191AA
+ Ipamorelin
ModerateIpamorelin (GHRP) stimulates endogenous GH release, which is redundant when exogenous rhGH is administered. However, ipamorelin may still amplify pulsatility of remaining endogenous secretion in partial GHD or during GH dose titration. Not typically combined in standard clinical practice; more common in experimental or off-label protocols. Limited evidence for additive benefit.
- HGH 191AA
- Standard dose per indication
- Ipamorelin
- 100–200 mcg SQ · morning (if used)
- Note
- Monitor IGF-1 closely; avoid supraphysiological levels
- Primary benefit
- Theoretical enhancement of pulsatility; limited clinical rationale
+ Tesamorelin
WeakTesamorelin (GHRH analogue) stimulates endogenous GH secretion, which is unnecessary when exogenous rhGH is already provided. Combining both offers no mechanistic advantage and increases cost, side effects, and IGF-1 elevation risk. Not recommended in clinical practice.
- Note
- Combination not recommended — choose one GH modality
- Primary benefit
- None — redundant mechanisms
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions